152 related articles for article (PubMed ID: 8091742)
1. Removal and inactivation of hepatitis A virus (HAV) during processing of factor VIII concentrates.
Hamman J; Zou J; Horowitz B
Vox Sang; 1994; 67 Suppl 1():72-6; discussion 77. PubMed ID: 8091742
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
3. Failure to detect hepatitis A virus RNA in factor VIII concentrates using the polymerase chain reaction. Results of a preliminary study.
McOmish F; Yap PL; Hart H; Peerlinck K; Burns SM; Simmonds P
Vox Sang; 1994; 67 Suppl 1():47-50. PubMed ID: 8091737
[TBL] [Abstract][Full Text] [Related]
4. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
Mosley JW
Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
[TBL] [Abstract][Full Text] [Related]
5. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
6. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
7. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source.
Kedda MA; Kew MC; Cohn RJ; Field SP; Schwyzer R; Song E; Fernandes-Costa F
Hepatology; 1995 Nov; 22(5):1363-7. PubMed ID: 7590648
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis A virus infection in tamarins: experimental transmission via contaminated factor VIII concentrates.
Chudy M; Stahl-Hennig C; Berger A; Nübling CM; Hunsmann G; Rabenau HF; Löwer J
J Infect Dis; 2002 Apr; 185(8):1170-3. PubMed ID: 11930328
[TBL] [Abstract][Full Text] [Related]
9. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
[TBL] [Abstract][Full Text] [Related]
11. Virology of the hepatitis A epidemic in Italy.
Purcell RH; Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU
Vox Sang; 1994; 67 Suppl 4():2-7; discussion 24-6. PubMed ID: 7831866
[TBL] [Abstract][Full Text] [Related]
12. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products.
Lemon SM
Vox Sang; 1994; 67 Suppl 4():19-23; discussion 24-6. PubMed ID: 7831865
[TBL] [Abstract][Full Text] [Related]
13. Detection of hepatitis A virus in a factor VIII preparation by antigen capture/PCR.
Normann A; Graff J; Flehmig B
Vox Sang; 1994; 67 Suppl 1():57-60; discussion 61. PubMed ID: 8091739
[TBL] [Abstract][Full Text] [Related]
14. Review of the hepatitis A epidemics in hemophiliacs in Europe.
Vermylen J; Peerlinck K
Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis A virus and blood products: virus validation studies.
Lemon SM
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S20-2. PubMed ID: 7495962
[TBL] [Abstract][Full Text] [Related]
16. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group.
Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU; Purcell RH
Ann Intern Med; 1994 Jan; 120(1):1-7. PubMed ID: 7504424
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis A in French hemophiliacs.
Goudemand J; Parquet A; d'Oiron R; Stieltjes N; Guérois C; Fonlupt J; Alcalay M; Négrier C; Cazenave JP; Briquel ME
Vox Sang; 1994; 67 Suppl 1():9-12; discussion 13. PubMed ID: 8091745
[TBL] [Abstract][Full Text] [Related]
18. Sequence variability of hepatitis A virus and factor VIII associated hepatitis A infections in hemophilia patients in Europe. An update.
Robertson BH; Friedberg D; Normann A; Graff J; Flehmig B; Shouval D
Vox Sang; 1994; 67 Suppl 1():39-45; discussion 46. PubMed ID: 8091736
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
20. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
